Journal
EXPERT OPINION ON DRUG DISCOVERY
Volume 4, Issue 7, Pages 763-784Publisher
INFORMA HEALTHCARE
DOI: 10.1517/17460440903018857
Keywords
anandamide; endocannabinoid; FAAH; FAAH inhibitor; fatty acid amides; serine hydrolase
Categories
Funding
- NIH [DA017295, DA015197]
Ask authors/readers for more resources
Back round: Fatty acid amide hydrolase (FAAH) is an integral membrane enzyme that hydrolyzes the endocannabinoid anandamide and related amidated signaling lipids. Genetic or pharmacological inactivation of FAAH produces analgesic, anti-inflammatory, anxiolytic and antidepressant phenotypes without showing the undesirable side effects of direct cannabinoid receptor agonists, indicating that FAAH may be a promising therapeutic target. Objectives: This review highlights advances in the development of FAAH inhibitors of different mechanistic classes and their in vivo efficacy. Also highlighted are advances in technology for the in vitro and in vivo selectivity assessment of FAAH inhibitors using activity-based protein profiling and click chemistry-activity-based protein profiling, respectively. Recent reports on structure-based drug design for human FAAH generated by protein engineering using interspecies active site conversion are also discussed. Methods: The literature searches of Medline and SciFinder databases were used. Conclusions: There has been tremendous progress in our understanding of FAAH and development of FAAH inhibitors with in vivo efficacy, selectivity and drug-like pharmacokinetic properties.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available